TransCode Therapeutics (NASDAQ: RNAZ)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-22 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.270 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of TransCode Therapeutics (NASDAQ: RNAZ) through any online brokerage.
Other companies in TransCode Therapeutics’s space includes: Biocept (NASDAQ:BIOC), Cyclacel Pharmaceuticals (NASDAQ:CYCC), Biophytis (NASDAQ:BPTS), Indaptus Therapeutics (NASDAQ:INDP) and Diffusion Pharmaceuticals (NASDAQ:DFFN).
The latest price target for TransCode Therapeutics (NASDAQ: RNAZ) was reported by HC Wainwright & Co. on Tuesday, June 7, 2022. The analyst firm set a price target for 10.00 expecting RNAZ to rise to within 12 months (a possible 700.00% upside). 1 analyst firms have reported ratings in the last year.
The stock price for TransCode Therapeutics (NASDAQ: RNAZ) is $1.25 last updated Today at June 30, 2022, 5:14 PM UTC.
There are no upcoming dividends for TransCode Therapeutics.
TransCode Therapeutics’s Q2 earnings are confirmed for Monday, August 22, 2022.
There is no upcoming split for TransCode Therapeutics.
TransCode Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.